Breaking News Instant updates and real-time market news.

2023-01-06 08:03:01 AHT Ashford Hospitality $4.13 / -0.26 (-5.93%) 08:03 01/06/23 01/06 08:03 01/06/23 08:03	Ashford Hospitality sees Q4 RevPAR approximately $118 Ashford Hospitality Trust reported that the company expects to report occupancy of approximately 68% for the fourth quarter of 2022 with an average daily rate of approximately $175 resulting in RevPAR of approximately $118. This RevPAR reflects an approximate increase of 25% compared to the fourth quarter of 2021 and a decrease of approximately 1% compared to the fourth quarter of 2019. Additionally, for the month of December 2022, RevPAR was essentially unchanged versus December 2019. For the month of November 2022, RevPAR decreased approximately 2% versus November 2019. For the month of October 2022, RevPAR decreased approximately 1% versus October 2019.	22 Feb

2023-01-06 08:03:01

AHT

Ashford Hospitality

$4.13 / -0.26 (-5.93%)

08:03

01/06/23

01/06

08:03

01/06/23

08:03

Ashford Hospitality sees Q4 RevPAR approximately $118

Ashford Hospitality Trust reported that the company expects to report occupancy of approximately 68% for the fourth quarter of 2022 with an average daily rate of approximately $175 resulting in RevPAR of approximately $118. This RevPAR reflects an approximate increase of 25% compared to the fourth quarter of 2021 and a decrease of approximately 1% compared to the fourth quarter of 2019. Additionally, for the month of December 2022, RevPAR was essentially unchanged versus December 2019. For the month of November 2022, RevPAR decreased approximately 2% versus November 2019. For the month of October 2022, RevPAR decreased approximately 1% versus October 2019.

22
Feb

OTHER BREAKING NEWS FROM THE FLY

Downgrade	First Foundation downgraded to Neutral from Overweight at Piper Sandler » 06:06 02/03/23 02/03 06:06 02/03/23 06:06 FFWM First Foundation $16.33 / +0.375 (+2.35%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options FFWM First Foundation $16.33 / +0.375 (+2.35%) 11/21/22 First Foundation announces CEO Scott Kavanaugh named president 11/08/22 First Foundation says president DePillo to leave, CFO Thompson named interim FFWM First Foundation $16.33 / +0.375 (+2.35%) 01/03/23 Stephens Castle Biosciences, Academy Sports on Stephens 'Best Ideas' list for 2023 10/26/22 DA Davidson First Foundation downgraded to Neutral from Buy at DA Davidson 07/27/22 B. Riley First Foundation price target raised to $23 from $21 at B. Riley 07/11/22 B. Riley First Foundation downgraded to Neutral from Buy at B. Riley FFWM First Foundation $16.33 / +0.375 (+2.35%) 01/26/23 First Foundation reports Q4 EPS 31c, consensus 31c 10/25/22 First Foundation reports Q3 EPS 51c, consensus 51c 02/07/23 Regional Banks Investor Trip FFWM First Foundation $16.33 / +0.375 (+2.35%) 09/21/22 Seventeen new option listings on September 21st
Earnings	Cigna sees FY23 adjusted EPS $24.60, consensus $24.84 » 06:06 02/03/23 02/03 06:06 02/03/23 06:06 CI Cigna $301.39 / -11.73 (-3.75%) Sees FY23 revenue at… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CI Cigna $301.39 / -11.73 (-3.75%) 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices 12/06/22 Walmart to pay $500,000 over workers' compensation prescription procedures 11/07/22 WBA to invest $3.5B to support VillageMD acquisition of Summit Healt-CityMD CI Cigna $301.39 / -11.73 (-3.75%) 01/31/23 JPMorgan Medicare Advantage final rule more favorable than feared, says JPMorgan 01/03/23 Wells Fargo Wells Fargo downgrades Cigna to Equal Weight, lowers price target to $355 01/03/23 Wells Fargo Cigna downgraded to Equal Weight from Overweight at Wells Fargo 11/23/22 Morgan Stanley Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley CI Cigna $301.39 / -11.73 (-3.75%) 06:02 Today Cigna reports Q4 adjusted EPS $4.96, consensus $4.86 02/02/23 Notable companies reporting before tomorrow's open 02/02/23 Notable companies reporting before tomorrow's open 11/03/22 Cigna raises FY22 adjusted EPS view to at least $23.10 from at least $22.90 CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/07/22 Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports 08/18/22 White House plans for end of COVID-19 vaccine coverage, WSJ reports CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 What You Missed On Wall Street This Morning 11/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Fly Intel: Pre-market Movers 08:30 Today Cigna - CI CI Cigna $301.39 / -11.73 (-3.75%) 01/13/23 Early notable gainers among liquid option names on January 13th
Syndicate	Quoin Pharmaceuticals files to sell $10M of ordinary shares » 06:05 02/03/23 02/03 06:05 02/03/23 06:05 QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) Represented by American… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 12/13/22 Quoin announces dosing of first patient in trial in Netherton Syndrome 11/03/22 Quoin Pharmaceuticals announces updated Q3 conference call timing 10/18/22 Quoin announces plans to initiate second trial in Netherton syndrome patients 09/13/22 Quoin Pharmaceuticals establishes patient specific website for ongoing study QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 09/07/22 Alliance Global Partners Quoin Pharmaceuticals initiated with a Buy at Alliance Global Partners 08/19/22 JMP Securities Quoin Pharmaceuticals price target lowered to $15 from $100 at JMP Securities 08/19/22 Maxim Quoin Pharmaceuticals price target lowered to $10 from $25 at Maxim 05/06/22 Ladenburg Ladenburg starts Quoin Pharmaceuticals at Buy with $2 price target QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 11/10/22 Quoin Pharmaceuticals reports Q3 ADS (94c) vs ($5.84) last year 08/18/22 Quoin Pharmaceuticals reports Q2 EPS ($3.24) vs. ($18.05) last year
Downgrade	Hexcel downgraded to Neutral from Buy at BofA » 06:05 02/03/23 02/03 06:05 02/03/23 06:05 HXL Hexcel $71.23 / +0.03 (+0.04%) BofA analyst Ronald… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HXL Hexcel $71.23 / +0.03 (+0.04%) 10/25/22 Coinbase launches USDC institutional rewards program with MakerDAO 10/24/22 Hexcel did not repurchase any common stock during Q3 HXL Hexcel $71.23 / +0.03 (+0.04%) 01/30/23 Jefferies Hexcel price target raised to $70 from $60 at Jefferies 01/30/23 Wells Fargo Hexcel price target raised to $70 from $60 at Wells Fargo 01/27/23 Truist Hexcel price target raised to $59 from $53 at Truist 01/09/23 Truist Hexcel price target raised to $53 from $52 at Truist HXL Hexcel $71.23 / +0.03 (+0.04%) 01/25/23 Hexcel sees FY23 EPS $1.70-$1.90, consensus $1.82 01/25/23 Hexcel reports Q4 EPS 40c, consensus 32c 10/24/22 Hexcel narrows FY22 adjusted EPS view to $1.12-$1.24 from $1.00-$1.24 10/24/22 Hexcel reports Q3 adjusted EPS 33c, consensus 33c HXL Hexcel $71.23 / +0.03 (+0.04%) 01/25/23 Fly Intel: After-Hours Movers 02/15/23 44th Annual Aerospace/Defense & Industrials Conference
Downgrade	Camden Property downgraded on 'market drag' at Piper Sandler » 06:04 02/03/23 02/03 06:04 02/03/23 06:04 CPT Camden Property $126.29 / +2.55 (+2.06%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events CPT Camden Property $126.29 / +2.55 (+2.06%) 10/10/22 Camden Property estimates $1.0M in expenses related to Hurricane Ian 09/30/22 Camden Property says early reports indicate minor damage from Hurricane Ian 09/30/22 Camden Property provides update on Hurricane Ian CPT Camden Property $126.29 / +2.55 (+2.06%) 02/02/23 Piper Sandler Camden Property downgraded to Neutral from Overweight at Piper Sandler 01/10/23 Mizuho Camden Property upgraded to Buy from Neutral at Mizuho 01/04/23 Deutsche Bank Camden Property price target lowered to $140 from $153 at Deutsche Bank 12/15/22 UBS Camden Property initiated with a Buy at UBS CPT Camden Property $126.29 / +2.55 (+2.06%) 02/02/23 Camden Property sees Q1 FFO $1.63-$1.67, consensus $1.75 02/02/23 Camden Property sees FY23 FFO $6.70-$7.00, consensus $7.17 02/02/23 Camden Property reports Q4 FFO $1.74, consensus $1.74 10/27/22 Camden Property see FY22 FFO $6.57-$6.61, consensus $6.63 08 Apr 03/08/23 Miami Property Tour 11:00 Today Camden Property - CPT
Downgrade	Ford downgraded to Sell from Hold at Deutsche Bank » 06:04 02/03/23 02/03 06:04 02/03/23 06:04 F Ford $14.34 / +0.535 (+3.88%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford sees FY23 capital expenditures $8B-$9B 02/02/23 Ford down 6% after Q4 earnings report 02/02/23 Ford declares regular Q1 dividend of 15c, supplemental dividend of 65c 02/02/23 Ford reports January U.S. sales up 2% to 146,356 vehicles F Ford $14.34 / +0.535 (+3.88%) 01/25/23 JPMorgan Ford price target lowered to $15 from $16 at JPMorgan 01/11/23 Goldman Sachs Goldman continues to prefer Tesla and GM among automakers 12/21/22 Morgan Stanley Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley 12/05/22 Jefferies Fox Factory price target raised to $135 from $120 at Jefferies F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford sees FY23 adjusted EBIT of $9B-$11B 02/02/23 Ford reports Q4 adjusted EPS 51c, consensus 62c 02/02/23 Notable companies reporting after market close 10/26/22 Ford reports Q3 adjusted EPS 39c, consensus 27c F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford's Jan. U.S. sales increased 2% y/y, saw 'record' EV sales, Bloomberg says 01/24/23 Ford in discussions to sell German factory to BYD, WSJ reports 01/23/23 Union says Ford to slash up to 3,200 European jobs, Reuters reports 01/23/23 Ford planning massive layoffs overseas in favor of EV development, Electrek says F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Fly Intel: After-Hours Movers 01/30/23 What You Missed On Wall Street On Monday 01/30/23 What You Missed On Wall Street This Morning 01/30/23 Here's what Wall St. experts are saying about these automakers ahead of earnings F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford options imply 5.2% move in share price post-earnings 01/17/23 Ford put volume heavy and directionally bearish 12/30/22 Notable open interest changes for December 30th 12/19/22 Unusually active option classes on open December 19th
Initiation	Herbalife Nutrition initiated with an Underperform at BofA » 06:03 02/03/23 02/03 06:03 02/03/23 06:03 HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) BofA analyst Anna Liznul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/06/22 Herbalife Nutrition falls -19.5% 12/06/22 Herbalife Nutrition falls -16.6% 12/06/22 Herbalife Nutrition falls -15.0% 12/05/22 Herbalife Nutrition falls 10% to $15.70 after offering $250M in convertible debt HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 11/01/22 B. Riley Herbalife Nutrition price target lowered to $31 from $38 at B. Riley 11/01/22 Citi Herbalife Nutrition price target lowered to $26 from $30 at Citi 10/05/22 Citi Herbalife Nutrition price target lowered to $30 from $36 at Citi 08/03/22 B. Riley Herbalife Nutrition price target lowered to $38 from $41 at B. Riley HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 10/31/22 Herbalife Nutrition reports Q3 EPS 91c, consensus 74c HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/06/22 What You Missed On Wall Street On Tuesday 12/06/22 What You Missed On Wall Street This Morning 12/06/22 Fly Intel: Pre-market Movers 12/05/22 Fly Intel: After-Hours Movers 03/21/23 6th Annual Consumer Growth Conference 02/14/23 Herbalife Nutrition - HLF HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/23/22 Herbalife put volume heavy and directionally bearish 10/31/22 Herbalife options imply 8.4% move in share price post-earnings
Hot Stocks	Vyant Bio announces reduction in force and other measures to preserve cash » 06:03 02/03/23 02/03 06:03 02/03/23 06:03 VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) Vyant Bio announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 01/04/23 Vyant Bio engages LifeSci Capital to explore strategic alternatives 11/16/22 Vyant Bio regains compliance with Nasdaq minimum bid requirement 11/07/22 Vyant Bio teams up with IRSF to host local viewing party 11/03/22 Vyant Bio sells vivoPharm subsidiary to Reaction for $5.5M VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 10/04/22 Ascendiant Vyant Bio initiated with a Buy at Ascendiant VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 11/15/22 Vyant Bio reports Q3 EPS (59c) vs (77c) last year 08/22/22 Vyant Bio reports Q2 EPS (20c) vs (14c) last year VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 01/05/23 Fly Intel: Pre-market Movers
Recommendations	Alphabet price target raised to $155 from $130 at Oppenheimer » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 GOOG Alphabet $108.77 / +7.375 (+7.27%) Oppenheimer analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet says started bringing revenue sharing to YouTube Shorts 02/02/23 Alphabet reports Q4 Google Cloud revenue $7.3B vs. $5.54B last year 02/02/23 Alphabet taking actions to optimize global office space 02/01/23 'Tomb Raider Reloaded' coming to Google Play, iOS, Netflix on February 14 GOOG Alphabet $108.77 / +7.375 (+7.27%) 04:30 Today Piper Sandler Alphabet price target lowered to $120 from $122 at Piper Sandler 02/02/23 Morgan Stanley Meta Platforms price target raised to $190 from $130 at Morgan Stanley 01/31/23 BofA Alphabet price target raised to $119 at BofA ahead of earnings 01/30/23 KeyBanc Trade Desk price target lowered to $55 from $56 at KeyBanc GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet reports Q4 EPS $1.05, consensus $1.18 02/02/23 Notable companies reporting after market close 10/25/22 Alphabet reports Q3 EPS $1.06, consensus $1.25 10/25/22 Notable companies reporting after market close GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Democratic senator joins calls to ban TikTok, WSJ reports 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Google testing ChatGPT-like products, including 'Apprentice Bard,' CNBC reports 01/31/23 Reels sharing revenue with creators hotly debated within Meta, Information says GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 What Wall Street is saying about Alphabet ahead of earnings 02/01/23 #SocialStocks: Meta circumvents FTC challenge and will acquire Within Unlimited GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet options imply 5.9% move in share price post-earnings 01/20/23 Unusually active option classes on open January 20th 12/14/22 Alphabet put buyer realizes 126% same-day gains 11/02/22 Alphabet put buyer realizes 98% same-day gains
Earnings	Cigna reports Q4 adjusted EPS $4.96, consensus $4.86 » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 CI Cigna $301.39 / -11.73 (-3.75%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CI Cigna $301.39 / -11.73 (-3.75%) 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices 12/06/22 Walmart to pay $500,000 over workers' compensation prescription procedures 11/07/22 WBA to invest $3.5B to support VillageMD acquisition of Summit Healt-CityMD CI Cigna $301.39 / -11.73 (-3.75%) 01/31/23 JPMorgan Medicare Advantage final rule more favorable than feared, says JPMorgan 01/03/23 Wells Fargo Wells Fargo downgrades Cigna to Equal Weight, lowers price target to $355 01/03/23 Wells Fargo Cigna downgraded to Equal Weight from Overweight at Wells Fargo 11/23/22 Morgan Stanley Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley CI Cigna $301.39 / -11.73 (-3.75%) 02/02/23 Notable companies reporting before tomorrow's open 02/02/23 Notable companies reporting before tomorrow's open 11/03/22 Cigna raises FY22 adjusted EPS view to at least $23.10 from at least $22.90 11/03/22 Cigna reports Q3 adjusted EPS $6.04, consensus $5.71 CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/07/22 Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports 08/18/22 White House plans for end of COVID-19 vaccine coverage, WSJ reports CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 What You Missed On Wall Street This Morning 11/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Fly Intel: Pre-market Movers 08:30 Today Cigna - CI CI Cigna $301.39 / -11.73 (-3.75%) 01/13/23 Early notable gainers among liquid option names on January 13th

Recommendations	Paylocity price target raised to $297 from $276 at Piper Sandler » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 PCTY Paylocity $226.21 / +6.61 (+3.01%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly Events PCTY Paylocity $226.21 / +6.61 (+3.01%) 11/04/22 KeyBanc Paylocity price target lowered to $295 from $310 at KeyBanc 10/28/22 DA Davidson Paylocity cut to Neutral at DA Davidson on valuation, expectations for softer Q1 10/28/22 DA Davidson Paylocity downgraded to Neutral from Buy at DA Davidson 10/24/22 Needham Needham adds Five9 to Conviction List, removes Paylocity PCTY Paylocity $226.21 / +6.61 (+3.01%) 02/02/23 Paylocity sees FY23 revenue $1.156B-$1.161B, consensus $1.12B 02/02/23 Paylocity sees Q3 revenue $330.5M-$334.5M, consensus $318.65M 02/02/23 Paylocity reports Q2 non-GAAP EPS $1.12, consensus 73c 11/03/22 Paylocity sees Q2 revenue $257M-$261M, consensus $254.69M PCTY Paylocity $226.21 / +6.61 (+3.01%) 02/02/23 Fly Intel: After-Hours Movers 03/06/23 Technology Conference
Earnings	Johnson Outdoors reports Q1 EPS 57c vs. $1.07 a year ago » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) Reports Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Events JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) 09/29/22 Johnson Outdoors raises quarterly cash dividend to 31c per share JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) 12/09/22 Johnson Outdoors reports Q4 EPS 95c vs. 68c a year ago 11:00 Today Johnson Outdoors - JOUT 03/01/23 Johnson Outdoors, Inc.
Downgrade	Direct Line Insurance downgraded to Underweight from Equal Weight at Barclays » 06:00 02/03/23 02/03 06:00 02/03/23 06:00 DIISY Direct Line Insurance $9.10 / +0.47 (+5.45%) Barclays analyst Ivan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research DIISY Direct Line Insurance $9.10 / +0.47 (+5.45%) 01/30/23 Berenberg Direct Line Insurance price target lowered to 159 GBp from 160 GBp at Berenberg 01/25/23 Berenberg Direct Line Insurance downgraded to Hold from Buy at Berenberg 01/24/23 UBS Direct Line Insurance price target lowered to 190 GBp from 194 GBp at UBS 01/24/23 Citi Direct Line Insurance downgraded to Sell from Neutral at Citi
Hot Stocks	Creative Media & Community Trust acquires three multifamily assets » 05:59 02/03/23 02/03 05:59 02/03/23 05:59 CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) CMCT announced that it is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) 08/15/22 CMCT signs long-term lease with O'Gara Coach for Beverly Hills showroom CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) 09/29/22 Edward Jones CIM Commercial Trust initiated with a Buy at Edward Jones
Recommendations	MAA price target raised to $190 from $180 at JMP Securities » 05:58 02/03/23 02/03 05:58 02/03/23 05:58 MAA MAA $173.90 / +5.49 (+3.26%) JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MAA MAA $173.90 / +5.49 (+3.26%) 12/13/22 MAA raises quarterly dividend 12% to $1.40 per share 10/19/22 MAA announces planned retirement of COO Thomas Grimes MAA MAA $173.90 / +5.49 (+3.26%) 01/17/23 Truist MAA downgraded to Hold from Buy at Truist 01/11/23 BTIG MAA price target lowered to $175 from $225 at BTIG 01/09/23 Credit Suisse MAA downgraded to Neutral from Outperform at Credit Suisse 01/03/23 Jefferies Independence Realty Trust downgraded at Jefferies on macro concerns MAA MAA $173.90 / +5.49 (+3.26%) 02/01/23 MAA sees Q1 core FFO $2.14-$2.30, consensus $2.25 02/01/23 MAA sees FY23 core FFO $8.88-$9.28, consensus $9.16 02/01/23 MAA reports Q4 core FFO $2.32, consensus $2.28 10/26/22 MAA sees Q4 core FFO $2.19-$2.35, consensus $2.20
Upgrade	H.B. Fuller upgraded to Buy from Neutral at Citi » 05:58 02/03/23 02/03 05:58 02/03/23 05:58 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) Citi analyst Eric Petrie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 09/26/22 H.B. Fuller names Celeste Mastin as new CEO 09/21/22 H.B. Fuller narrows FY22 adjusted EBITDA view to $540M-$550M from $530M-$550M FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/23/23 Citi H.B. Fuller price target raised to $72 from $65 at Citi 01/20/23 Deutsche Bank H.B. Fuller price target raised to $78 from $72 at Deutsche Bank 01/20/23 Baird H.B. Fuller price target lowered to $80 from $85 at Baird 10/13/22 Baird H.B. Fuller margins biased higher despite macro evironment, says Baird FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 H.B. Fuller sees FY23 adjusted EPS $4.15-$4.55, consensus $4.63 01/18/23 H.B. Fuller reports Q4 adjusted EPS $1.04, consensus $1.24 09/21/22 H.B. Fuller sees Q4EPS $1.15-$1.30, consensus $1.28 09/21/22 H.B. Fuller reports Q3 EPS $1.06, consensus $1.04 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 Fly Intel: After-Hours Movers 09/22/22 What You Missed On Wall Street This Morning 09/22/22 Fly Intel: Pre-market Movers 09/21/22 Fly Intel: After-Hours Movers
Hot Stocks	XPeng launches G9 SUV, P7 sports sedan in European markets » 05:57 02/03/23 02/03 05:57 02/03/23 05:57 XPEV XPeng $11.05 / -0.09 (-0.81%) XPeng launched its two… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XPEV XPeng $11.05 / -0.09 (-0.81%) 02/01/23 XPeng delivers 5,218 Smart EVs in January 01/06/23 XPeng falls -15.8% 01/06/23 XPeng falls -16.1% 01/06/23 XPeng falls -11.3% XPEV XPeng $11.05 / -0.09 (-0.81%) 01/11/23 JPMorgan XPeng downgraded to Neutral from Overweight at JPMorgan 01/06/23 BofA XPeng downgraded to Neutral at BofA after Tesla price cuts 01/06/23 BofA XPeng downgraded to Neutral from Buy at BofA 01/04/23 Wedbush Demand issues, Twitter focus creates 'perfect storm' for Tesla, says Wedbush XPEV XPeng $11.05 / -0.09 (-0.81%) 11/30/22 XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B 11/30/22 XPeng reports Q3 EPS (36c), consensus (36c) 08/23/22 XPeng sees Q3 revenue RMB6.8B-RMB7.2B, up 18.9%-25.9% from last year 08/23/22 XPeng reports Q2 no-GAAP EPS (43c), consensus ($2.61) XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 XPeng follows Tesla with price cuts in China, Reuters reports 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 What You Missed On Wall Street On Tuesday 01/17/23 What You Missed On Wall Street This Morning 01/17/23 What You Missed This Week in EVs and Clean Energy 01/17/23 Fly Intel: Pre-market Movers XPEV XPeng $11.05 / -0.09 (-0.81%) 01/30/23 XPeng call volume above normal and directionally bullish 01/27/23 XPeng call volume above normal and directionally bullish 01/24/23 XPeng call volume above normal and directionally bullish 01/23/23 XPeng call volume above normal and directionally bullish
Downgrade	Repare Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 01/19/23 Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/17/22 H.C. Wainwright Repare Therapeutics price target lowered to $25 from $38 at H.C. Wainwright 06/06/22 H.C. Wainwright Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 04/12/22 Stifel Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis' RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/09/22 Repare Therapeutics reports Q3 EPS $1.71, consensus (89c)
General news	Energy Action: » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 $ECON Economic Data / + Energy Action: Oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals On The Fly $ECON Economic Data / + $ECON Economic Data / + 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says 01/22/23 Fed sets course for milder interest-rate rise next month, WSJ says 11/04/22 Fed's Evans says smaller rate hikes make sense, Reuters reports 10/22/22 Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says $ECON Economic Data / + 02/01/23 What You Missed On Wall Street On Wednesday 01/24/23 What You Missed On Wall Street On Tuesday 01/18/23 What You Missed On Wall Street On Wednesday 12/15/22 What You Missed On Wall Street On Thursday
Upgrade	Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley » 05:54 02/03/23 02/03 05:54 02/03/23 05:54 NBIX Neurocrine $107.96 / -2.045 (-1.86%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBIX Neurocrine $107.96 / -2.045 (-1.86%) 01/09/23 Xenon Pharmaceuticals outlines key milestone opportunities for 2023 01/09/23 Voyager, Neurocrine enter collaboration to advance multiple gene therapies 12/22/22 Neurocrine: FDA accepts sNDA for valbenazine 12/06/22 Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/13/22 RBC Capital Neurocrine CAH data appears pushed back, says RBC Capital 11/14/22 Evercore ISI Neurocrine downgraded to In Line from Outperform at Evercore ISI 11/02/22 BMO Capital Neurocrine price target raised to $101 from $78 at BMO Capital 11/02/22 Wells Fargo Neurocrine price target raised to $120 from $110 at Wells Fargo NBIX Neurocrine $107.96 / -2.045 (-1.86%) 11/01/22 Neurocrine reports Q3 non-GAAP EPS $1.08, consensus 79c 08/04/22 Neurocrine reports Q2 non-GAAP EPS 84c, consensus 15c NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/06/22 Fly Intel: After-Hours Movers 09/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/06/23 Biotech Ski Summit 02/06/23 Neurocrine - NBIX

Downgrade	Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 IMRX Immuneering $4.16 / +0.05 (+1.22%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/28/22 Immuneering doses first patient in Phase 1/2a trial of IMM-1-104 11/10/22 Immuneering presents preclinical data on its second program IMM-6-415 10/20/22 Immuneering names Leah Neufeld as Chief People Officer 09/30/22 Immuneering: FDA clears IND for Phase 1/2a clinical trial of IMM-1-104 IMRX Immuneering $4.16 / +0.05 (+1.22%) 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 09/30/22 Piper Sandler Immuneering transitions to clinical stage with IND approval, says Piper Sandler 07/25/22 Piper Sandler Immuneering CFO departure not a 'red flag,' says Piper Sandler 07/08/22 Chardan Immuneering initiated with a Buy at Chardan IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/10/22 Immuneering expects FY22 GAAP operating expenses $53M-$56M 11/10/22 Immuneering reports Q3 EPS (49c), consensus (49c)
Earnings	Sanofi sees 2023 business EPS up at low single digit rate at CER » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 SNY Sanofi $47.22 / -1.505 (-3.09%) Sanofi expects 2023… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 05:52 Today Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Esperion upgraded to Equal Weight from Underweight at Morgan Stanley » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 ESPR Esperion $5.91 / -0.49 (-7.66%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ESPR Esperion $5.91 / -0.49 (-7.66%) 01/11/23 RFK Racing enters team-wide partnership with Esperion 12/07/22 Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL 11/16/22 Esperion promotes Ben Halladay to CFO role 08/26/22 Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force ESPR Esperion $5.91 / -0.49 (-7.66%) 12/07/22 H.C. Wainwright H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint 08/03/22 Credit Suisse Esperion downgraded to Underperform from Neutral at Credit Suisse 05/04/22 JPMorgan Esperion upgraded to Neutral on achievable estimates at JPMorgan 05/04/22 JPMorgan Esperion upgraded to Neutral from Underweight at JPMorgan ESPR Esperion $5.91 / -0.49 (-7.66%) 01/08/23 Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M 11/01/22 Esperion reports Q3 EPS (81c), consensus (92c) ESPR Esperion $5.91 / -0.49 (-7.66%) 12/09/22 Biotech Alert: Searches spiking for these stocks today 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ESPR Esperion $5.91 / -0.49 (-7.66%) 01/06/23 Esperion call volume above normal and directionally bullish 12/19/22 Esperion put volume heavy and directionally bearish 12/07/22 Unusually active option classes on open December 7th 11/17/22 Largest borrow rate increases among liquid names
Earnings	Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 SNY Sanofi $47.22 / -1.505 (-3.09%) IFRS EPS for Q4 was EUR… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Erasca upgraded to Overweight from Equal Weight at Morgan Stanley » 05:51 02/03/23 02/03 05:51 02/03/23 05:51 ERAS Erasca $4.16 / +0.165 (+4.13%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Syndicate On The Fly ERAS Erasca $4.16 / +0.165 (+4.13%) 12/20/22 Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/13/22 Erasca announces FDA clearance of IND application for ERAS-3490 12/09/22 Erasca announces pricing of underwritten offering of common stock 12/09/22 Erasca, Novartis enter worldwide license agreement for naporafenib ERAS Erasca $4.16 / +0.165 (+4.13%) 11/09/22 Erasca reports Q3 EPS (29c), consensus (31c) 09 Dec ERAS Erasca $4.16 / +0.165 (+4.13%) 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning

Events

Earnings calls, analyst events, roadshows and more

AVTR
Today at 08:00

Avantor - AVTR Conference Calls
TWST
Today at 08:00

Twist Bioscience - TWST Conference Calls
SNY
Today at 08:00

Sanofi - SNY Conference Calls
Today at 08:30

Employment Situation: Average Workweek: January 2023 Government Event
Today at 08:30

Employment Situation: Private Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Manufacturing Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Participation Rate: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings Y/Y: January 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	VERA X VERA Vera Therapeutics Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LIFC Priced at: $7.00 14.286M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ALGM X ALGM Allegro MicroSystems Block Trade Managers: Credit Suisse Priced at: $38.00 4.98M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPCR X GPCR Structure Therapeutics IPO Managers: Jefferies, SVB Securities, Guggenheim & BMO Capital Priced at: $15.00 10.74M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ROIV X ROIV Roivant Sciences Secondary Managers: Goldman Sachs, SVB Securities, Cowen & Cantor Fitzgerald Priced at: $7.50 26.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AVTX X AVTX Avalo Therapeutics Spot Secondary Managers: SVB Securities & RBC Capital Priced at: $3.98 3.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDBL X EDBL Edible Garden Spot Secondary Managers: Maxim & Joseph Gunnar Priced at: $6.30 1.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	WULF X WULF TeraWulf Spot Secondary Managers: JonesResearch $1.03
Thurs	ASST X ASST Asset Entities IPO Managers: Boustead $5.00 1.5M Shares SODR X SODR Sondors IPO Managers: DA Davidson & Lake Street $8.00 - 10.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDXH X MDXH MDxHealth Secondary Managers: Cowen & William Blair, BTIG, KBCS $6.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CLLS X CLLS Cellectis Spot Secondary Managers: Jefferies & Barclays $3.26 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWO X TWO Two Harbors Spot Secondary Managers: Goldman Sachs, JPMorgan & Citi, JMP Securities $17.80-18.00 10M Shares
Fri	No deals

View All Syndicate Announcements »

Ashford Hospitality sees Q4 RevPAR approximately $118

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access